Route28 Summit in Neurobiology 2002

(Stem-) cell-based therapeutic approaches for Parkinson’s Disease


[Background] [Speakers] [Schedule]



(as of July 25, 2002)



August 22, 2002, evening

Anders Björklund

Wallenberg Neuroscience Center, Lund University, Lund, Sweden

A giant leap — Bringing cell-based therapies for Parkinson’s disease from the lab bench to the clinics





August 23, 2002, morning

Jürgen Winkler

Dept. of Neurology, University of Regensburg, Regensburg, Germany

New strategies for Parkinson disease - Introduction to the assigned questions and topics




H. Georg Kuhn

Dept. of Neurology, University of Regensburg, Regensburg, Germany


Gerd Kempermann

Dept. of Neurology, Charité University Hospital, Humboldt University, and Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany

Adult neurogenesis




Mark Noble

Dept of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY, U.S.A.

The primal regulator hypothesis and its relationship to understanding

precursor cell function in development, repair and CNS damage induced by chemotherapy





August 23, 2002, afternoon

The first part of this session will be dedicated to talks from two for­mer student participants of Route28. The participants can discuss their thoughts on how to proceed with their proposal with the former students.




Andreas Hartmann

Dept. of Neurology, Philipps University Marburg, Marburg, Germany

Is there cellular regeneration in the adult substantia nigra?




Josef Priller

Dept. of Neurology, Charité University Hospital, Humboldt University, Berlin, Germany

Blood to brain: bone-marrow stem cells as a tool for reconstructive neurobiology




Carolee Barlow

Laboratory of Genetics, The Salk Institute, La Jolla Ca., U.S.A.


Gene arrays in stem cell research



August 23, 2002, evening

A game based on “Six degrees of separation” encourages interac­tion and exchange between group members.





August 24, 2002, morning

Marie-Francoise Chesselet

Dept of Neurology, Reed Neurological Research Center, UCLA School of Medicine, University of California Los Angeles, Los Angeles, CA, U.S.A.

Cellular biology and Parkinson’s Disease




Wolfgang Wurst

GSF-Institute of Mammalian Genetics, Neuherberg, Germany.

Genetic models for neurological disease




Ole Isacson, Neuroregeneration Laboratory, Harvard Medical School, Boston Ma., U.S.A.

Dopaminergic differentiation of stem cells



August 24, 2002, afternoon

Patrik Brundin, Wallenberg Neuroscience Center, Lund University, Lund, Sweden

Learning to survive — Transplantation strategies for Parkinson’s Disease




Oliver Brüstle

Neuropathologisches Institut, Universität Bonn, Germany

Embryonic stem cells in reconstructive neurobiology



August 24, 2002, evening

Poster session I

In the two poster sessions the participants have the opportunity to present their own data and interests to fellow students and faculty members





August 25, 2002, morning

Lars Wahlberg

NsGene, Copenhagen, Denmark

Think big — Stem cells as a biotechnological product




Andreas Kupsch

Dept. of Neurology, Charité University Hospital, Humboldt University, Berlin, Germany

Why bother with cells? — Perspectives on deep brain stimulation




Thomas Gasser, Dept. of Neurology, Ludwig Maximilans Universität, München, Germany

Which genes matter? — Neurogenetic implications for cell-based therapies



August 25, 2002, afternoon

Wolfgang Oertel

Dept. of Neurology, Philipps University Marburg, Marburg, Germany

What do Parkinson patients really need? What can researchers really provide?




Guido Nikkhah

Dept. of Neurosurgery, Albert-Ludwigs- Universität Freiburg, Freiburg i.Br., Germany

How to rebuild the dopaminergic system — from single cell to organotypic reconstruction




David Lockart

Ambit Biosciences, San Diego, CA, U.S.A.

Gene arrays revisited: practical considerations



August 25, 2002, evening

Poster session II





August 26, 2002, morning

Roger Barker

Addenbrooke's Hospital, Cambridge, U.K.

Of pigs and mice — the future of xenotransplantation in Parkinson’s Disease




Theo Palmer

Stanford University, Palo Alto, California, U.S.A.

The human factor — how to deal with human stem cells in vitro and in vivo




Christian Schwägerl

Frankfurter Allgemeine Zeitung, Berlin, Germany

Dealing in and with stem cells — the commercial side of it


The remainder of the day will be used by the groups to finalize their proposals, on which they have worked during the preceding days. As many faculty members as possible are present to discuss with the groups. Faculty and organizers are strictly neutral in the competi­tion and share their knowledge with everybody alike. They have to be asked, however, and will not volunteer their knowledge.

At 6 P.M. the proposals will be handed in. The jury will convene in the evening and discuss the proposals. At the same time, the students have time to prepare for their oral presentation.





August 27, 2002, morning

Each of the nine groups has ten minutes for an oral presentation of their submitted proposal. Only handwritten overheads are allowed, no Powerpoint presentations. After the presentation, the jury will have ten minutes for questions to the group members. After this the jury deliberates.




Gretchen Vogel

Correspondent SCIENCE magazine in Germany, Berlin, Germany

Discussion on issues like real-life funding, publishing, public opinion on stem cells, and the impact of research politics




The afternoon is used for an excursion to Herrenchiemsee. During this time the organizing committee prepares the awards and orga­nizes the concluding ceremony and banquet in the evening.



August 27, 2002, evening

Award presentation and Banquet





August 28, 2002, morning


[Background] [Speakers] [Schedule]